ArticleScientific reports2021
Relationship of continuous glucose monitoring-related metrics with HbA1c and residual β-cell function in Japanese patients with type 1 diabetes.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Correlation between time on target and glycated hemoglobin in people with diabetes mellitus: systematic review.Revista latino-americana de enfermagem · 2023Pooled it
- Association Between Glycemic Parameters and Severity of Periodontitis in Nepal: A Hospital-Based Cross-Sectional Study.International journal of dentistry · 2026Article
- Rapid and Slow Progressors Toward β-Cell Depletion and Their Predictors in Type 1 Diabetes: Prospective Longitudinal Study in Japanese Type 1 Diabetes (TIDE-J).Diabetes care · 2025Article
- Identification of Adipsin as a Biomarker of Beta Cell Function in Patients with Type 2 Diabetes.Journal of clinical medicine · 2024Article
- Beyond HbA1c: Identifying Gaps in Glycemic Control Among Children and Young People with Type 1 Diabetes Using Continuous Glucose Monitoring.Indian journal of pediatrics · 2024Article
- Residual β-Cell Function Is Associated With Longer Time in Range in Individuals With Type 1 Diabetes.Diabetes care · 2024Article
- Glucose values from the same continuous glucose monitoring sensor significantly differ among readers with different generations of algorithm.Scientific reports · 2024Article
- Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on "time in range" in patients with type 2 diabetes.Frontiers in pharmacology · 2024Article
- Glycemic Excursion and Insulin Action Revealed in a Rare Case of Type 1 Diabetes Complicated with Short Bowel Syndrome.Internal medicine (Tokyo, Japan) · 2023Article
- Antidiabetic activity ofFrontiers in pharmacology · 2023Article
- Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model.Frontiers in pharmacology · 2023Article
- Metabolic signatures of β-cell destruction in type 1 diabetes.Journal of diabetes investigation · 2023Observational
- Preserved C-peptide secretion is associated with higher time in range (TIR) on intermittently scanned continuous glucose monitoring in Chinese adults with type 1 diabetes.Endocrine connections · 2022Article
- Insulin-dependent diabetes mellitus in older adults: Current status and future prospects.Geriatrics & gerontology international · 2022Review
- Capturing the real-world benefit of residual β-cell function during clinically important time-periods in established Type 1 diabetes.Diabetic medicine : a journal of the British Diabetic Association · 2022Article
- Analysis of detrended fluctuation function derived from continuous glucose monitoring may assist in distinguishing latent autoimmune diabetes in adults from T2DM.Frontiers in endocrinology · 2022Article
- Insulin Requirement and Complications Associated With Serum C-Peptide Decline in Patients With Type 1 Diabetes Mellitus During 15 Years After Diagnosis.Frontiers in endocrinology · 2022Article
- β-Cell failure in diabetes: Common susceptibility and mechanisms shared between type 1 and type 2 diabetes.Journal of diabetes investigation · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The targets for continuous glucose monitoring (CGM)-derived metrics were recently set; however, studies on CGM data over a long period with stable glycemic control are limited. We analyzed 194,279 CGM values obtained from 19 adult Japanese patients with type 1 diabetes. CGM data obtained during stable glycemic control over four months were analyzed. CGM-related metrics of different durations "within 120, 90, 60, 30, and 7 days" were calculated from baseline. Time in range (TIR; glucose 70-180 mg/dL), time above range (TAR; glucose ≥ 181 mg/dL), and average glucose levels, but not time below range (TBR; glucose ≤ 69 mg/dL), strongly correlated with glycated hemoglobin (HbA1c) values (P < 0.0001). TBR correlated with glucose coefficient of variation (CV) (P < 0.01). Fasting serum C-peptide levels negatively correlated with glucose CV (P < 0.01). HbA1c of approximately 7% corresponded to TIR of 74% and TAR of 20%. The shorter the CGM period, the weaker was the relationship between HbA1c and CGM-related metrics. TIR, TAR, and average glucose levels accurately reflected HbA1c values in Japanese patients with type 1 diabetes with stable glycemic control. Glucose CV and TBR complemented the limitation of HbA1c to detect glucose variability and hypoglycemia. Stable glycemic control with minimal hypoglycemia depended on residual β-cell function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.